Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Laila Aldars-García und 41 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria del Hospital de La Princesa, Universidad Autónoma de Madrid, Centro de In…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Sara Borrell, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background and Aims Inflammatory bowel disease (IBD) is a prevalent chronic noncurable disease associated with profound metabolic changes. The discovery of novel molecular indicators for unraveling IBD etiopathogenesis and the diagnosis and prognosis of IBD is therefore pivotal. We sought to determine the distinctive metabolic signatures from the different IBD subgroups before treatment initiation.
Methods
Serum and urine samples from newly diagnosed treatment-naïve IBD patients and age and sex-matched healthy control (HC) individuals were investigated using proton nuclear magnetic resonance spectroscopy. Metabolic differences were identified based on univariate and multivariate statistical analyses.
Results
A total of 137 Crohn’s disease patients, 202 ulcerative colitis patients, and 338 HC individuals were included. In the IBD cohort, several distinguishable metabolites were detected within each subgroup comparison. Most of the differences revealed alterations in energy and amino acid metabolism in IBD patients, with an increased demand of the body for energy mainly through the ketone bodies. As compared with HC individuals, differences in metabolites were more marked and numerous in Crohn’s disease than in ulcerative colitis patients, and in serum than in urine. In addition, clustering analysis revealed 3 distinct patient profiles with notable differences among them based on the analysis of their clinical, anthropometric, and metabolomic variables. However, relevant phenotypical differences were not found among these 3 clusters.
Conclusions
This study highlights the molecular alterations present within the different subgroups of newly diagnosed treatment-naïve IBD patients. The metabolomic profile of these patients may provide further understanding of pathogenic mechanisms of IBD subgroups. Serum metabotype seemed to be especially sensitive to the onset of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria del Hospital de La Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, M…
- Precision Medicine and Metabolism Lab, CIC bioGUNE, Derio, Spain.
- Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
- Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Marqués de Valdecilla, Santander, Spain.
- Hospital General Universitario de Alicante, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain.
- Hospital Universitario de Galdakao, Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
ORCID-Profile: Daniel Ceballos, Fernando Bermejo, María Chaparro
Förderung
- Sara Borrell
- Instituto de Salud Carlos III
Zitieren
APA
Aldars-García, L., Gil-Redondo, R., Embade, N., Riestra, S., Rivero, M., Gutiérrez, A., Rodríguez-Lago, I., Fernández-Salazar, L., Ceballos, D., Manuel Benítez, J., Aguas, M., Baston-Rey, I., Bermejo, F., José Casanova, M., Lorente, R., Ber, Y., Ginard, D., Esteve, M., de Francisco, R., …, & Chaparro, M. (2024). Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad154
Vancouver
Aldars-García L, Gil-Redondo R, Embade N, Riestra S, Rivero M, Gutiérrez A, et al. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad154
BibTeX
@article{AldarsGarca2024,
author = {Aldars-García, Laila and Gil-Redondo, Rubén and Embade, Nieves and Riestra, Sabino and Rivero, Montserrat and Gutiérrez, Ana and Rodríguez-Lago, Iago and Fernández-Salazar, Luis and Ceballos, Daniel and Manuel Benítez, José and Aguas, Mariam and Baston-Rey, Iria and Bermejo, Fernando and José Casanova, María and Lorente, Rufo and Ber, Yolanda and Ginard, Daniel and Esteve, María and de Francisco, Ruth and García, María José and Francés, Rubén and Rodríguez Pescador, Ainhoa and Velayos, Benito and Del Río, Elena Guerra and Marín Pedrosa, Sandra and Minguez Sabater, Alejandro and Barreiro-de Acosta, Manuel and Algaba, Alicia and Verdejo Gil, Cristina and Rivas, Olga and Royo, Vanesa and Aceituno, Montserrat and Garre, Ana and Baldán-Martín, Montserrat and Ramírez, Cristina and Sanz-García, Ancor and Lozano, Juan J and Sidorova, Julia and Millet, Oscar and Bernardo, David and Gisbert, Javier P and Chaparro, María},
title = {Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad154}
}
EUVIMED